Morgan Stanley Starts CRISPR Therapeutics (CRSP) at Underweight
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $53.55 -0.81%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Underweight rating and a price target of $37.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $60.82 yesterday.
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
- Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
